OBJECTIVE: The purpose of this study was to evaluate prospectively the depiction of hypervascular hepatocellular carcinoma on 64-MDCT scans obtained with contrast agents of varying iodine concentrations administered with and without saline flush. SUBJECTS AND METHODS: The study included 149 patients, among whom 36 patients with hypervascular hepatocellular carcinoma were identified. Patients were randomly assigned to one of three protocols: A, contrast material of 300 mg I/mL; B, 370 mg I/mL; C, 370 mg I/mL plus saline flush. In all protocols, the same iodine load per kilogram of body weight (516 mg/kg) was administered for the same injection duration (30 seconds). Enhancement values in the aorta, liver, and portal vein and tumor-liver contrast were measured at multiphase CT. RESULTS:Aortic enhancement was significantly different between protocols A and B (p = 0.04, p < 0.0001) and protocols B and C (p = 0.02, p < 0.001) in the first and second phases. Portal venous enhancement was significantly different between protocols B and C (p = 0.02) in the first phase and between protocols B and C and protocols A and C (p < 0.01, p = 0.02) in the second phase. Tumor-liver contrast was significantly different between protocols A and B (p = 0.03, p = 0.02) and protocols B and C (p = 0.03, p = 0.04) in the first and second phases but not between protocols A and C. There was no significant difference in hepatic enhancement among the three protocols. CONCLUSION: Use of moderate concentration was more effective than use of a high concentration of contrast material for depiction of hepatocellular carcinoma. Adding a saline flush to the high-concentration protocol eliminated the difference in depiction of hepatocellular carcinoma between the moderate- and high-concentration protocols.
RCT Entities:
OBJECTIVE: The purpose of this study was to evaluate prospectively the depiction of hypervascular hepatocellular carcinoma on 64-MDCT scans obtained with contrast agents of varying iodine concentrations administered with and without salineflush. SUBJECTS AND METHODS: The study included 149 patients, among whom 36 patients with hypervascular hepatocellular carcinoma were identified. Patients were randomly assigned to one of three protocols: A, contrast material of 300 mg I/mL; B, 370 mg I/mL; C, 370 mg I/mL plus salineflush. In all protocols, the same iodine load per kilogram of body weight (516 mg/kg) was administered for the same injection duration (30 seconds). Enhancement values in the aorta, liver, and portal vein and tumor-liver contrast were measured at multiphase CT. RESULTS: Aortic enhancement was significantly different between protocols A and B (p = 0.04, p < 0.0001) and protocols B and C (p = 0.02, p < 0.001) in the first and second phases. Portal venous enhancement was significantly different between protocols B and C (p = 0.02) in the first phase and between protocols B and C and protocols A and C (p < 0.01, p = 0.02) in the second phase. Tumor-liver contrast was significantly different between protocols A and B (p = 0.03, p = 0.02) and protocols B and C (p = 0.03, p = 0.04) in the first and second phases but not between protocols A and C. There was no significant difference in hepatic enhancement among the three protocols. CONCLUSION: Use of moderate concentration was more effective than use of a high concentration of contrast material for depiction of hepatocellular carcinoma. Adding a salineflush to the high-concentration protocol eliminated the difference in depiction of hepatocellular carcinoma between the moderate- and high-concentration protocols.
Authors: A Guerrisi; D Marin; R C Nelson; G De Filippis; M Di Martino; H Barnhart; R Masciangelo; I Guerrisi; R Passariello; C Catalano Journal: Br J Radiol Date: 2011-08 Impact factor: 3.039
Authors: Laura Cosmai; Camillo Porta; Carmelo Privitera; Loreto Gesualdo; Giuseppe Procopio; Stefania Gori; Andrea Laghi Journal: ESMO Open Date: 2020-03